SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ESLA

Estrella Immunopharma, Inc. (NASDAQ:ESLA)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.32-$0.02 (-5.70%)
 
Market cap
$14.1M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 14, 2021
Market Cap$14.11M-82.3%
Revenue (ttm)$0
Net Income-$12.59M+6.7%
EPS-$0.29+22.0%
Shares Out43.97M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume251,677
Open$0.36
Previous Close$0.34
Day's Range$0.32 - $0.40
52-Week Range$0.24 - $2.27
Beta0.89
AnalystsBuy
Price Targetn/a
Earnings DateMar 16, 2027

About ESLA

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.

Address
5858 Horton Street, EmeryVille, CA, 94608, US
Market Cap
14 million
Employees
3
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$2.59K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Weak
From ESLA’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-5.70%
5 Days
-35.62%
1 Month
-55.83%
6 Months
-72.33%
1 Year
-82.27%

$ESLA stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ESLA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ESLA's directors and management

Net Shares Purchased by Insiders−1k−50002025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ESLA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ESLA Revenue by Segment

$7.25MTotal
Clinical trial related service fee to related party (Note 5)$6.88M94.86%
Professional fee$251.69K3.47%
Stock-based compensation (Note 8)$105.63K1.46%
Consulting fee$15.00K0.21%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New ESLA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ESLA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ESLA

VTIVanguard Morningstar Total Stock Market ETF$135.32K
VXFVanguard Extended Market ETF$94.77K
IWCiShares Micro-Cap ETF$15.35K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ESLA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
100% of score
60
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
3
Sells
0
Buy Value
$2.59K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.